PharVision Advisers’s Booz Allen Hamilton BAH Stock Holding History

PharVision Advisers’s Portfolio BAH Stock Details BAH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-6,467	Closed	-$832K	–	292
2024 Q4	$832K	Buy	+6,467	New	+$1M	0.7%	9

Other funds holding BAH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

PharVision Advisers's BAH Position: Q1 2025 in Review

PharVision Advisers sold out of Booz Allen Hamilton (BAH) in Q1 2025, closing a stake of 6,467 shares — an estimated $832K sold.

PharVision Advisers first reported a position in BAH in Q4 2024 and held it in 1 quarter. The position peaked at $832K in Q4 2024. 727 funds tracked by Wall St. Rank hold BAH as of Q1 2025.

PharVision Advisers reported no remaining Booz Allen Hamilton position as of Q1 2025 after selling out during the quarter.
PharVision Advisers sold 6,467 Booz Allen Hamilton shares in Q1 2025, an estimated $832K.
PharVision Advisers first reported a position in Booz Allen Hamilton in Q4 2024 and held it in 1 quarter.
PharVision Advisers's Booz Allen Hamilton position peaked at $832K in Q4 2024.
727 funds tracked by Wall St. Rank held Booz Allen Hamilton as of Q1 2025.

Based on PharVision Advisers's 13F filing for Q1 2025, filed 15 May 2025.